Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J7EB | ISIN: FR0011341205 | Ticker-Symbol: 5NR
Tradegate
31.03.25
11:45 Uhr
3,272 Euro
-0,044
-1,33 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOBIOTIX SA Chart 1 Jahr
5-Tage-Chart
NANOBIOTIX SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,2063,27021:45
3,2063,27021:45

Aktuelle News zur NANOBIOTIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoNanobiotix S.A.: NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 20251
DoNanobiotix reports promising NSCLC treatment study results1
DoNanobiotix S.A. - 6-K, Report of foreign issuer1
DoNanobiotix S.A.: Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC232Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of...
► Artikel lesen
18.03.Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden3
NANOBIOTIX Aktie jetzt für 0€ handeln
18.03.Nanobiotix tweaks J&J licensing deal for phase 3 cancer drug to eke out cash13
17.03.Nanobiotix S.A.: NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026107PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic...
► Artikel lesen
13.03.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
13.03.Nanobiotix S.A. - 6-K, Report of foreign issuer1
12.02.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company1
12.02.Nanobiotix S.A. - 6-K, Report of foreign issuer-
29.01.Nanobiotix S.A. - 6-K, Report of foreign issuer-
21.01.Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study1
21.01.Nanobiotix S.A. - 6-K, Report of foreign issuer5
21.01.Nanobiotix S.A.: NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer177PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based...
► Artikel lesen
10.01.Nanobiotix S.A. - 6-K, Report of foreign issuer-
09.01.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company1
17.12.24Nanobiotix S.A.: NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 20242
17.12.24Nanobiotix S.A. - 6-K, Report of foreign issuer2
11.12.24Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1